Information:
Error:
ID
33355
Description
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01206881
Link
https://clinicaltrials.gov/show/NCT01206881
Keywords
Versions (1)
- 12/6/18 12/6/18 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
December 6, 2018
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Breast Cancer NCT01206881
Eligibility Breast Cancer NCT01206881
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01206881
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Breast Carcinoma
Item
pathologically proven breast cancer
boolean
C0678222 (UMLS CUI [1])
Locally advanced breast cancer inflammatory | Tumor Size
Item
inflammatory, locally advanced breast cancer or a tumor > 5 cm
boolean
C3495949 (UMLS CUI [1,1])
C0333348 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
C0333348 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status < 2
boolean
C1520224 (UMLS CUI [1])
Left ventricular ejection fraction MUGA | Patients HER2 Positive
Item
lvef > 50% measured by muga (her2 positive patients)
boolean
C0428772 (UMLS CUI [1,1])
C0521317 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
C0521317 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
Bone Marrow function | Liver function | Renal function
Item
adequate bone marrow, liver and renal function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Informed Consent
Item
written informed consent must be obtained
boolean
C0021430 (UMLS CUI [1])
Cancer Other
Item
another malignancy within 5 years prior to study entry
boolean
C1707251 (UMLS CUI [1])
Investigational New Drugs
Item
concurrent treatment with an investigational agent
boolean
C0013230 (UMLS CUI [1])
Disease Study Subject Participation Status Contraindicated | Condition Study Subject Participation Status Contraindicated
Item
other disease or condition that contraindicates participation in the study
boolean
C0012634 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444657 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444657 (UMLS CUI [2,3])
C2348568 (UMLS CUI [1,2])
C1444657 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444657 (UMLS CUI [2,3])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])